Asegua Therapeutics

Executive Summary

Asegua Therapeutics, founded in 2018 and based in Cambridge, MA, is a private generic drug company focused on expanding access to hepatitis C therapies. The company markets authorized generics of two leading Gilead drugs: ledipasvir/sofosbuvir (the authorized generic of Harvoni) and sofosbuvir/velpatasvir (the authorized generic of Epclusa). By offering these lower-cost alternatives, Asegua aims to capture a meaningful share of the hepatitis C treatment market, which remains underserved due to high branded drug costs despite curative therapies being available. As a private entity, the company operates with minimal public disclosure and a lean business model, relying on established manufacturing and distribution partnerships to bring these generics to patients and payers. The hepatitis C generic market is growing as patent expirations and value-based care drive demand for affordable options. Asegua's authorized generics benefit from the established safety and efficacy profiles of the reference drugs, lowering regulatory and commercial risk. However, the company faces competition from other generic entrants and potential price erosion. Its success hinges on securing favorable formulary placements and distribution agreements with pharmacy benefit managers (PBMs) and health systems. While the financial details remain undisclosed, Asegua's strategic focus on high-volume, high-impact generics positions it for steady revenue growth, albeit within a concentrated market subject to pricing dynamics and patent litigation.

Upcoming Catalysts (preview)

• Q2 2026New PBM or Health System Formulary Inclusion70% success
• Q4 2026Launch of Third Authorized Generic (Hepatitis C or Adjacent Therapy)30% success
• Q3 2026Publication of Real-World Evidence on Cost Savings vs. Branded Therapies60% success